COMMUNIQUÉS West-GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2023
29/02/2024
Cash and cash equivalents totaled €77.8 million as of December 31, 2023 Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA action date for [...]
GENFIT annonce son chiffre d’affaires et sa position de trésorerie au 31 décembre 2023
29/02/2024
Trésorerie et équivalents de trésorerie : 77,8 millions d’euros au 31 décembre 2023 Chiffre d’affaires : 28,6 millions d’euros au 31 décembre 2023, dont un paiement d’étape de 13,3 millions d’euros Date d’action PDUFA [...]
RadNet Reports Fourth Quarter 2023 Results, Including Record Revenue and Adjusted EBITDA(1), Releases 2024 Financial Guidance and Forms a New Digital Health Reporting Segment
29/02/2024
Revenue increased 9.5% to a record $420.4 million in the fourth quarter of 2023 from $383.9 million in the fourth quarter of 2022; Excluding Revenue from the Artificial Intelligence (“AI”) reporting segment, Revenue [...]
Certara Reports Fourth Quarter 2023 Financial Results
29/02/2024
Provides Full Year 2024 Financial Guidance PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter [...]
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
29/02/2024
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS- [...]
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
29/02/2024
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company discontinued the [...]
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
29/02/2024
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company [...]
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
29/02/2024
WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the [...]
Alvotech Appoints Interim Chief Quality Officer
29/02/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate [...]
Alvotech Appoints Interim Chief Quality Officer
29/02/2024
REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29/02/2024
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into [...]
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
29/02/2024
Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at 4:30 p.m. Eastern time [...]
Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
29/02/2024
LAKE FOREST, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective [...]
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
29/02/2024
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the trial - - Initial [...]
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
29/02/2024
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory NHL [...]
ProKidney to Participate in Jefferies Biotech on the Bay Summit
29/02/2024
WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced [...]
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
29/02/2024
CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29/02/2024
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in Q4 2024- -Upcoming Type- [...]
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
29/02/2024
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]

Pages